Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06826768 · ClinicalTrials.gov registry record · Phase 1

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

A Phase 1 study of Prostate Cancer, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT06826768: Recruiting Phase 1 study of Prostate Cancer, sponsored by M.D. Anderson Cancer Center.

NCT06826768 is a Phase 1 study of Prostate Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 60 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06826768, a Phase 1 study of Prostate Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

A single-center phase Ib/II dose escalation and dose-expansion clinical trial of REGN5678 plus cemiplimab

Conditions Studied

Prostate Cancer

Interventions

  • DRUG Cemiplimab
  • DRUG REGN5678

Study Locations (1)

Texas

  • The University of Texas M. D. Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-07-09
Est. Completion 2029-05-01
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06826768

The ClinicalTrials.gov registry entry for NCT06826768 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.

NCT06826768 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06826768 about?

NCT06826768 is a clinical study titled "A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC". A single-center phase Ib/II dose escalation and dose-expansion clinical trial of REGN5678 plus cemiplimab

What is the current status of trial NCT06826768?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-07-09. Estimated completion is 2029-05-01.

What conditions does trial NCT06826768 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT06826768?

The interventions under investigation include: Cemiplimab (DRUG), REGN5678 (DRUG).

Who is sponsoring clinical trial NCT06826768?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06826768 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.